Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

2.080 -0.090 (-4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,711
Open 2.060
Bid (Size) 2.080 (2)
Ask (Size) 2.130 (5)
Prev. Close 2.170
Today's Range 2.060 - 2.240
52wk Range 1.870 - 4.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lisata Therapeutics Announces Research License with Catalent
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-41.7%
-41.7%
1 Month
-12.6%
-12.6%
3 Month
-42.9%
-42.9%
6 Month
-29.3%
-29.3%
1 Year
-26.5%
-26.5%

More News

Read More
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 27, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Lisata Therapeutics
Via Benzinga
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
Via Benzinga
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?
Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?
Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?
The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market
What is the current price of Lisata Therapeutics, Inc. - Common Stock?
The current price of Lisata Therapeutics, Inc. - Common Stock is 2.080
When was Lisata Therapeutics, Inc. - Common Stock last traded?
The last trade of Lisata Therapeutics, Inc. - Common Stock was at 04/16/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.